Renal Outcomes of GLP-1 Receptor Agonists and Tirzepatide Across CKD Stages and Metabolic Phenotypes (Type 2 Diabetes and/or Overweight/Obesity): A Scoping Review.

Diabetes Ther · 2026 · PMC13103125 · PMID 41848820

Europe PMC DOI

hedged sentence

0.0160

closest p · 0.3× alpha

0.0160

boldest claim

The sentences

a favorable trendP = 0.016actually significant

In the larger phase 2b trial ( n = 248, 26 weeks), cotadutide 300–600 μg daily achieved dose-dependent reductions in UACR (− 44% to − 50%) and a favorable trend in eGFR slope at the highest dose ( P = 0.016) compared with placebo.

also in 1,335 other papers

Quoted from the open-access full text in Europe PMC under the licence the publisher applied. The sentence is reproduced exactly as published; the emphasis is ours.